All In Biotech

Drug Trial Radar · NCT05470868

Safety and Tolerability of PRO-185

Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-185 When Applied on the Ocular Surface of Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Feb 4, 2023

Primary completion

May 22, 2023

Study completion May 22, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.

Conditions

  • Hyperemia Eye

Interventions

  • Naphazoline / Hypromellose OphthalmicDrug

    Naphazoline 0.03% / Hypromellose 0.2%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP) IncrementTime frame: Baseline visit (BV), day 1(pre and post pupil dilation); Visit 1 (V1), day 3 +1 (pre and post research product application); Visit 2 (V2), day 8 (pre and post research product application); Final Visit, day 10 (+1)
  2. Heart Rate IncrementTime frame: Baseline visit, day 1(pre and post pupil dilation); Visit 1, day 3 +1 (pre and post research product application); Visit 2, day 8 (pre and post research product application); Final Visit, day 10 (+1)
  3. Blood Pressure Increment (Systolic)Time frame: Baseline visit, day 1(pre and post pupil dilation); Visit 1, day 3 +1 (pre and post research product application); Visit 2, day 8 (pre and post research product application); Final Visit, day 10 (+1)
  4. Incidence of Conjunctival HyperemiaTime frame: Trough Day 10 (+1)
  5. Incidence of Pharmacological MydriasisTime frame: Trough Day 10 (+1)
  6. Blood Pressure Increment (Diastolic)Time frame: Baseline visit, day 1(pre and post pupil dilation); Visit 1, day 3 +1 (pre and post research product application); Visit 2, day 8 (pre and post research product application); Final Visit, day 10 (+1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IIMET Investigación e Innovación en Medicina Translacional

    Guadalajara, Jalisco, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.